staceywhite, Author at European Medical Journal - Page 27 of 195

Nemolizumab in Atopic Dermatitis

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

10 Mar 2025

How Does the Efficacy of Different Therapies Compare Across Patient Subgroups?

A network meta-analysis of incretin-based therapies in type 2 diabetes

Ending the HIV Epidemic

The possibility of ending the HIV epidemic in Europe is more tangible than ever, but the actions we take now will determine whether we go…

Legacy and Innovation: Pivotal Role of Complement in gMG and AQP4-Ab+ NMOSD – A Video Series

The Future of Food Allergy: Hugh Sampson

What initially drew you to the field of allergy and immunology, and how did your focus come to centre on food allergic disorders? I got…

Clinical Updates on Cerliponase Alfa ▼ in Children with CLN2 Disease

This infographic details the presentation, progression, and treatment of neuronal ceroid lipofuscinosis Type 2 (CLN2 disease), a…

A Roadmap for Clear Skin

Notable recent additions to dermatologists’ acne toolkit include newer dual and triple combination therapies, as well as agents with…

Optimising Patient Outcomes in Advanced Gastrointestinal Stromal Tumours (GIST) in Europe

Optimising Patient Outcomes in Advanced Gastrointestinal Stromal Tumours (GIST) in Europe

The European Society for Medical Oncology (ESMO) guidelines recommend life-long systemic tyrosine kinase inhibitor (TKI) therapies for…

Whipple’s Disease: One of Medicine’s Great Imitators

Following an admission to the authors’ centre with severe anaemia, duodenal biopsy confirmed the diagnosis of Whipple’s disease…

Retracted: Ozanimod▼ in Ulcerative Colitis: Key New Data

This article has now been retracted and a retraction statement has been published.